R&D Trends

Chesapeake Urology raises $100,000 for Urology Care Foundation

Monday, June 30, 2014 03:34 PM

Sanford Siegel, M.D., president and CEO of Chesapeake Urology Associates, presented the Urology Care Foundation with $114,248 in support of its prostate cancer research efforts. The funds were raised through the Zero Prostate Cancer Challenge (ZPCC) 10K/5K run in September 2013. The Urology Care Foundation is the official foundation of the American Urological Association (AUA)—an organization of roughly 20,000 urologists.

More... »

WIRB Copernicus Group

Liomont, Oncobiologics partner to launch biosimilars in Mexico

Friday, June 27, 2014 11:13 AM

Oncobiologics, a privately held biopharmaceutical company, and Laboratorios Liomont, a Mexico City-based pharmaceutical company, have partnered for the development, manufacture and commercialization of biosimilar monoclonal antibody products for the Mexican market. The agreement includes exclusive commercialization in Mexico by Liomont of two biosimilars developed by Oncobiologics.

More... »

CRF Health eCOA webinar series

Corgenix, VHFC receive $2.9M NIH grant to develop Ebola rapid diagnostic test kit

Friday, June 27, 2014 11:10 AM

Corgenix Medical, a worldwide developer and marketer of diagnostic test kits, has been awarded a three-year, $2.9 million NIH grant to advance the development of an Ebola rapid diagnostic test kit. Collaborating with Corgenix on the program will be members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University and partially funded by the NIH.

More... »

Battelle, BIO find bioscience industry has strong growth prospects

Thursday, June 26, 2014 02:18 PM

A study by Battelle and BIO analyzing the U.S. bioscience industry growth over the last 11 years—through recession and early economic recovery—reveals positive trends. The industry demonstrated a strong record of growth from 2001 to 2012, has navigated the deep economic recession better than most industries and is once again growing.

More... »

Debiopharm, Nobelex Biotech collaborate

Thursday, June 26, 2014 02:14 PM

Debiopharm Group, a Switzerland-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, and Nobelex Biotech, a Canadian company focusing on the discovery and early development of novel antimicrobial drugs, are collaborating on two discovery programs to develop antibiotics targeting Neisseria gonorrhoeae and enteric species utilizing a novel mechanism of action.

More... »

Regional Immunotherapy Discovery Program launched by Northeast cancer centers

Thursday, June 26, 2014 02:10 PM

Physician researchers from Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C., and John Theurer Cancer Center (JTCC) in Hackensack, N.J., have formed the Regional Immunotherapy Discovery Program.

More... »

Johnson & Johnson, Dana-Farber launch $10 million lung cancer collaboration

Thursday, June 26, 2014 02:03 PM

Johnson & Johnson Innovation, Boston, and Janssen Biotech have announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute. Janssen scientists will work with the research team at Dana-Farber's Belfer Institute for Applied Cancer Science to determine the clinical setting for certain immuno-oncology agents in Janssen's lung cancer discovery pipeline.

More... »

Report: Global biotechnology industry needs new paradigm for drug R&D

Wednesday, June 25, 2014 02:11 PM

The global biotechnology industry rebounded strongly in 2013, with public companies achieving double-digit revenue growth and a sharp increase in funds raised. However, much of the industry's growth was driven by a relatively small group of commercial stage companies, increasing the urgency for the rest of the industry to achieve greater efficiency in their drug development efforts. These are some of the key findings of Beyond borders: unlocking value, EY's 28th annual biotechnology industry report.

More... »

Mersana Therapeutics, Merck ink $792 million agreement

Wednesday, June 25, 2014 02:08 PM

Mersana Therapeutics and the biopharmaceutical division of Merckhave agreed to collaboratively develop next-generation antibody-drug conjugates (ADCs). ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody specifically targets and delivers the cytotoxic drug to cancer cells, which could lead to higher drug levels at the tumor site.

More... »

UC San Diego initiates Cal-BRAIN program

Wednesday, June 25, 2014 01:55 PM

The California budget signed by Gov. Jerry Brown on June 20 created a statewide research grants program called Cal-BRAIN, an initiative led by UC San Diego. With an initial allocation of $2 million, Cal-BRAIN—short for California Blueprint for Research to Advance Innovations in Neuroscience—is a state complement to the federal BRAIN Initiative announced by President Barack Obama in April 2013. It aims to accelerate the development of brain mapping techniques, including the development of new technologies.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs